| 10/15/2013 | CV | Market Commentary: Savient collapses after bankruptcy filing; MolyCorp drops; Resource, SolarCity on tap
|
| 10/15/2013 | CVDDHY | Savient Pharmaceuticals bankrupt, gets $55 million lead bid for assets
|
| 10/15/2013 | CV | Market Commentary: Midday Commentary: Planned Resource Capital looks cheap; Savient files Chapter 11
|
| 3/19/2013 | CVHY | Savient says cash is enough to operate through first half of 2014
|
| 7/23/2012 | CVDD | Savient says court rules no event of default on 4.75% convertibles
|
| 6/22/2012 | CV | Market Commentary: Patriot Coal continues to weaken; Onyx extends gains; Royal Gold slips in line; K-V drops
|
| 6/8/2012 | CVDD | Savient Pharmaceuticals holders allege default on 4.75% convertibles
|
| 5/9/2012 | CVLM | Savient holders exchange $108 million of 4.75% convertible notes
|
| 4/4/2012 | CVHYPF | Savient files $100 million shelf covering stock, debt and preferreds
|
| 2/27/2012 | CV | Market Commentary: Dendreon drops on outlook; Cheniere gains on Blackstone investment; DealerTrack to price
|
| 2/24/2012 | CV | Market Commentary: Interpublic slips in active trade on call; Salesforce.com active, lower; Savient weakens
|
| 12/30/2011 | CV | Outlook 2012: Convertibles primary market set for weakness without higher rates, stronger economy
|
| 12/30/2011 | CV | Outlook 2012: MF Global's two convertibles deals: A 'black eye' for the market
|
| 12/14/2011 | CV | Market Commentary: Lower-quality names succumb to selling; Savient drops; Cheniere up on secondary offering
|
| 11/14/2011 | CV | Market Commentary: Central European Distribution, Savient extend losses; Newer Human Genome premium rises
|
| 5/6/2011 | CV | Market Commentary: Lam Research issues expand on hedged basis on debuts; energy names expand on lower oil
|
| 2/7/2011 | CV | Market Commentary: Beckman 'comes in' on hedge; Chesapeake up on planned asset sale talk; MF Global on tap
|
| 2/4/2011 | CV | Savient greenshoe exercised, lifts 4.75% convertibles to $230 million
|
| 2/2/2011 | CV | Market Commentary: EMC, Amgen paper steady to higher; Savient extends gains; D.R. Horton, Lennar in trade
|
| 2/1/2011 | CV | New Issue: Savient prices upsized $200 million seven-year convertibles to yield 4.75%, up 25%
|
| 2/1/2011 | CV | Market Commentary: Upsized Savient jumps on debut; Avatar prices 7.5% convertibles; ADM gains after earnings
|
| 1/31/2011 | CV | Market Commentary: Massey Energy up on merger; Alpha Natural off; Savient upsizes; Avatar, Hovnanian on tap
|
| 1/31/2011 | CV | Savient Pharmaceuticals plans upsized $175 million seven-year convertibles at 4.5%-5%, up 20%-25%
|
| 9/24/2007 | CVHY | Savient Pharmaceuticals files $200 million shelf
|
